- Home
- CLNN vs SCYX Comparison
CLNN vs SCYX Comparison
Compare CLNN & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLNN
- SCYX
- Stock Information
- Founded
- CLNN 2012
- SCYX 1999
- Country
- CLNN United States
- SCYX United States
- Employees
- CLNN N/A
- SCYX N/A
- Industry
- CLNN Biotechnology: Pharmaceutical Preparations
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- CLNN Health Care
- SCYX Health Care
- Exchange
- CLNN Nasdaq
- SCYX Nasdaq
- Market Cap
- CLNN 43.0M
- SCYX 50.3M
- IPO Year
- CLNN N/A
- SCYX 2014
- Fundamental
- Price
- CLNN $4.68
- SCYX $1.06
- Analyst Decision
- CLNN Strong Buy
- SCYX Buy
- Analyst Count
- CLNN 4
- SCYX 1
- Target Price
- CLNN $55.25
- SCYX N/A
- AVG Volume (30 Days)
- CLNN 69.1K
- SCYX 297.8K
- Earning Date
- CLNN 03-12-2025
- SCYX 11-06-2024
- Dividend Yield
- CLNN N/A
- SCYX N/A
- EPS Growth
- CLNN N/A
- SCYX N/A
- EPS
- CLNN N/A
- SCYX N/A
- Revenue
- CLNN $421,000.00
- SCYX $8,566,000.00
- Revenue This Year
- CLNN N/A
- SCYX N/A
- Revenue Next Year
- CLNN N/A
- SCYX $365.06
- P/E Ratio
- CLNN N/A
- SCYX N/A
- Revenue Growth
- CLNN N/A
- SCYX N/A
- 52 Week Low
- CLNN $3.82
- SCYX $0.90
- 52 Week High
- CLNN $11.00
- SCYX $3.07
- Technical
- Relative Strength Index (RSI)
- CLNN 44.03
- SCYX 39.85
- Support Level
- CLNN $4.75
- SCYX $1.12
- Resistance Level
- CLNN $5.06
- SCYX $1.49
- Average True Range (ATR)
- CLNN 0.37
- SCYX 0.11
- MACD
- CLNN -0.07
- SCYX -0.01
- Stochastic Oscillator
- CLNN 3.59
- SCYX 10.42
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements).
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.